BLA 125294 · Sicor Biotech
Granix
Tbo-Filgrastim · Injection · Leukocyte Growth Factor
NovelLast checked: Nov 20, 2026Latest source record: Nov 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Aug 29, 2012
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
1,183
191 Phase 3, 62 recruiting
FAERS reports
871
542 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 30, 2023.
GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 )
Mechanism: Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Tbo-Filgrastim" as an intervention, any sponsor and status, largest first.
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPivotal-lookingRecruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT00785525 · 60,000 participants (planned) · Start Feb 1997 · Primary completion Jan 2030
Drug: Filgrastim · For: Healthy
Sites: Boca Raton, Florida; Rockville, Maryland; Minneapolis, Minnesota · 4 sites in all
- Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial InfarctionPivotal-lookingStatus unknown
Recardio, Inc.Industry
NCT05881382 · 4,100 participants (planned) · Start Sep 2023 · Primary completion Sep 2025
Drug: Dutogliptin + Filgrastim; Placebo · For: ST Elevation Myocardial Infarction
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT00070564 · 3,294 participants · Start Nov 2003 · Primary completion Jan 2015
Drug: pegfilgrastim; AC regimen and 3 more · For: Breast Cancer
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 542 sites in all
- Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney CancerPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002611 · 3,031 participants · Start Jul 1995 · Primary completion Jun 2002
Drug: dactinomycin; filgrastim and 4 more · For: Kidney Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 235 sites in all
- Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00014222 · 2,104 participants · Start Dec 4, 2000 · Primary completion Feb 10, 2014
Drug: epoetin alfa; filgrastim and 5 more · For: Breast Cancer
Sites: Fort Smith, Arkansas; Little Rock, Arkansas; La Jolla, California · 78 sites in all
- Combination Chemotherapy in Treating Patients With Breast CancerPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00003088 · 2,005 participants · Start Sep 1997 · Primary completion Apr 2003
Drug: cyclophosphamide; doxorubicin hydrochloride and 1 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Peoria, Illinois; Urbana, Illinois · 19 sites in all
- Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00004128 · 2,000 participants (planned) · Start Sep 1999 · Primary completion Jan 2008
Drug: aldesleukin; filgrastim and 5 more · For: Leukemia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 23 |
| 2015 | 46 |
| 2016 | 58 |
| 2017 | 62 |
| 2018 | 113 |
| 2019 | 115 |
| 2020 | 120 |
| 2021 | 130 |
| 2022 | 61 |
| 2023 | 54 |
| 2024 | 37 |
| 2025 | 25 |
| 2026 | 27 |
Recalls
1 FDA enforcement reports for this application.
Jan 10, 2025 · Class II · Ongoing
Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Granix (Tbo-Filgrastim)
2024 spending
$4.5M
Beneficiaries
2,050
5,220 claims
Per beneficiary
$2,172
$239.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,189,446 |
| 2021 | $2,788,563 |
| 2022 | $2,634,694 |
| 2023 | $2,335,129 |
| 2024 | $4,452,419 |
Part B: Granix (Tbo-Filgrastim) · HCPCS J1447
2024 spending
$2.9M
Beneficiaries
2,992
13,183 claims
Per beneficiary
$964
2024 ASP limit $0.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,486,718 |
| 2021 | $4,997,448 |
| 2022 | $4,369,262 |
| 2023 | $3,378,907 |
| 2024 | $2,885,527 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ, Bohlke K, Lyman GH, et al. · J Clin Oncol 2015 · Practice Guideline, Research Support, Non-U.S. Gov't
- Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R, Bias P, Mueller U, et al. · Support Care Cancer 2016 · Meta-Analysis
- Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK, Fiala MA, Grossman BJ, et al. · Biol Blood Marrow Transplant 2017 · Clinical Trial, Phase II, Randomized Controlled Trial
- A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy.
Federman N, Dragomir MD, Kizyma Z, et al. · J Pediatr Hematol Oncol 2019 · Clinical Trial, Phase II, Multicenter Study
- A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.
Adar L, Avisar N, Lammerich A, et al. · Drug Des Devel Ther 2015 · Comparative Study, Randomized Controlled Trial
Sponsor: Sicor Biotech
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.